HIV Infections Clinical Trial
Official title:
Telehealth to Reduce Suicidality and Improve HIV Care Engagement in Tanzania
Verified date | December 2023 |
Source | Duke University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The overall objectives of the proposed research are to develop a brief telehealth counseling intervention to provide support for people living with HIV and experiencing suicidal ideation, and to support HIV care engagement. The investigators hypothesize that a brief telehealth counseling intervention will be safe (participants in the clinical trial will not have increased risk of suicidal behavior), acceptable (high patient retention and satisfaction, high fidelity), and will demonstrate preliminary efficacy (reduced suicidal ideation, improved care engagement, improved mental well-being).
Status | Active, not recruiting |
Enrollment | 60 |
Est. completion date | March 31, 2025 |
Est. primary completion date | December 8, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 18 years of age or older - Attending HIV care at study clinic - Screen positive for suicidal ideation - Able to understand Kiswahili or English - Medically stable - Capable of providing informed consent to participate Exclusion Criteria: - Under 18 years old - Unable to understand Kiswahili or English - Experiencing medical or psychiatric symptoms requiring immediate treatment - Incapable of providing informed consent to participate |
Country | Name | City | State |
---|---|---|---|
Tanzania | Majengo Health Centre | Moshi | |
Tanzania | Mawenzi Hospital | Moshi |
Lead Sponsor | Collaborator |
---|---|
Duke University | Kilimanjaro Christian Medical Centre, Tanzania, National Institute of Mental Health (NIMH) |
Tanzania,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Suicidal Ideation | Columbia-Suicide Severity Rating Scale (C-SSRS), 6 items, scale 0 to 6 with higher indicating more ideation | 3 months post enrollment | |
Primary | HIV Care Engagement | Self-reported clinic attendance | 3 months post enrollment | |
Primary | HIV Medication Adherence | Self-reported medication adherence | 3 months post enrollment | |
Secondary | Depression | Patient Health Questionnaire (PHQ-9), 9 items, score 0-27 with higher indicating more depression | 3 months post enrollment | |
Secondary | HIV Stigma | HIV Stigma Scale (HSS), 12 items, score 12-48 with higher indicating more stigma | 3 months post enrollment | |
Secondary | HIV Acceptance | Illness Cognition Questionnaire (ICQ), 6 items, score 0-18 with higher indicating more acceptance | 3 months post enrollment | |
Secondary | HIV Disclosure | Self-reported disclosure to partner, family, friends, others (yes/no) and total number of disclosures | 3 months post enrollment | |
Secondary | Social Support | Perceived Availability of Support Scale (PASS), 7 items, score 7 to 35 with higher indicating more social support | 3 months post enrollment | |
Secondary | Attitudes About Antiretroviral Therapy | Beliefs About Medicine Questionnaire (BMQ), 10 items, score 10 to 50 with higher indicating more positive attitudes about medication | 3 months post enrollment | |
Secondary | Acceptability of Intervention | 10 items adapted from the Client Satisfaction Questionnaire (CSQ), score 10 to 40 with higher indicating greater satisfaction with the intervention | 3 months post enrollment | |
Secondary | Suicide Coping Self-Efficacy | Self-Efficacy to Avoid Suicidal Action (SEASA) Scale, 6 items, score 0 to 60 with higher indicating more coping self-efficacy | 3 months post enrollment | |
Secondary | Hopelessness | Beck Hopelessness Scale (Balsamo Short Form), 9 items, score 0 to 9 with higher indicating more hopelessness | 3 months post enrollment | |
Secondary | Reasons for Living | Brief Reasons for Living Inventory, 12 items, score 12 to 72 with higher indicating more reasons to live | 3 months post enrollment | |
Secondary | Anxiety | Brief Symptom Inventory Anxiety Subscale, 6 items, score 0 to 24 with higher indicating more anxiety | 3 months post enrollment | |
Secondary | Quality of Life (Overall and Health Satisfaction) | WHOQOL-BREF, 2 items, score 2 to 10 with higher indicating better quality of life | 3 months post enrollment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |